Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DM13V0P)

Drug Name

Rivoceranib Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Gastric adenocarcinoma	2B72	Phase 3	[1]
Sarcoma	2A60-2C35	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1	[1]

Cross-matching ID

Molecule(s) Related to This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Vascular endothelial growth factor receptor 2 (KDR)	TTUTJGQ	VGFR2_HUMAN	Antagonist	[1]

------------------------------------------------------------------------------------

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease

Gastric adenocarcinoma

ICD Disease Classification

2B72

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Vascular endothelial growth factor receptor 2 (KDR)	DTT	KDR	1.98E-01	0.11	0.2

Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2	ClinicalTrials.gov (NCT04072042) BIOmarker Driven Trial of VEGFR2 Inhibitor in Advanced Sarcoma (BIOVAS). U.S. National Institutes of Health.